Dasatinib

Dasatinib is an oral multi-target tyrosine kinase inhibitor — originally approved for chronic myeloid leukemia — that the longevity and aesthetics-focused community uses off-label as the "D" in the D+Q senolytic protocol (dasatinib + quercetin). The oncology mechanism and the senolytic mechanism overlap but are used very differently: CML patients are dosed daily for years; physique-focused and health-optimization users pulse it for two to three days, quarterly, and let it clear. Understanding why that hit-and-run dosing works requires understanding what the molecule is actually doing to senescent cells.

Tyrosine Kinase Inhibition — the Original Pharmacology#

At the molecular level, dasatinib is an ATP-competitive inhibitor of several tyrosine kinase families: BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It wedges into the ATP-binding pocket of these kinases and shuts down their phosphorylation activity. In CML this kills the leukemic clone. In a healthy adult running a senolytic pulse, the relevant targets are the SRC-family kinases and ephrin receptors expressed on senescent cells as part of their anti-apoptotic survival machinery.

"Following oral dosing, dasatinib exhibits a terminal half-life of 3–4 h, high protein binding, and pH-dependent absorption, with CYP3A4 as the main enzyme responsible for metabolism." — Lindauer A, Di Gion P, Kanefendt F, et al. Clin Pharmacokinet (2010)

The short half-life is the reason pulsed dosing works at all — three days of coverage hits the senescent-cell population, then the drug clears before the chronic-exposure toxicities (pleural effusion, myelosuppression, QT prolongation) that CML patients accumulate have time to take hold.

Selective Apoptosis of Senescent Cells (the Senolytic Mechanism)#

Senescent cells are the ones that have stopped dividing but refuse to die — they sit in tissue pumping out inflammatory cytokines (the SASP: IL-6, MCP-1, TNFα, MMPs) that drive "inflammaging," joint degradation, tendon stiffness, skin aging, and blunted recovery. They survive because they upregulate senescent cell anti-apoptotic pathways (SCAPs) — ephrin/SRC-family signalling, PI3K/AKT, and BCL-2-family dependence — that keep them above the apoptotic threshold.

Dasatinib knocks out the ephrin/SRC arm. Quercetin knocks out the BCL-2/PI3K arm. Neither hits every senescent-cell subtype on its own, which is why the protocol is always D+Q, not D alone.

"Dasatinib and quercetin (D+Q) selectively induced apoptosis of senescent human preadipocytes and endothelial cells, providing proof-of-concept for senolytics targeting key survival pathways in senescent cells." — Zhu Y, Tchkonia T, Pirtskhalava T, et al. Aging Cell (2015)

Practically: this is why they are used together, why skipping the quercetin dose defeats the protocol, and why the validated human trials all use the combination.

SASP Suppression and Systemic Inflammation#

Clearing senescent cells isn't just about killing bad actors locally — it drops the circulating cytokine load the rest of your body is marinating in. In the Mayo diabetic-kidney-disease trial, short-term intermittent D+Q measurably reduced senescent-cell burden in adipose tissue and skin and lowered circulating SASP factors.

"Senescent cell abundance in adipose tissue and skin was reduced after short-term intermittent dasatinib plus quercetin administration, with decreases in circulating SASP factors in subjects with diabetic kidney disease." — Hickson LJ, Langhi Prata LGP, Bobart SA, et al. EBioMedicine (2019)

For a physique-focused user, the relevant translation is: lower chronic IL-6 and TNFα means better recovery between sessions, less tendon stiffness, cleaner lipid panels, and reduced anabolic resistance. Senescent cells in aged muscle and adipose tissue actively suppress satellite-cell function — clearing them is mechanistically aligned with wanting to hold onto muscle and train hard into your 40s and beyond.

"Hit-and-Run" Kinetics — Why Pulsed Dosing Works#

The critical pharmacological insight that makes this compound usable outside oncology is that senolytic killing does not require sustained drug exposure. Once a senescent cell is pushed past the apoptotic threshold, it commits — the drug doesn't need to stick around. Senescent cells then take weeks to accumulate back to baseline.

"Senolytics such as dasatinib with quercetin eliminate senescent cells in mice and humans, improving physical function, and are typically administered intermittently due to the delayed accumulation of senescent cells." — Kirkland JL, Tchkonia T. J Intern Med (2020)

This is why the protocol is 100 mg + 1000 mg × 2–3 consecutive days, every 4 weeks early on, then quarterly for maintenance — not daily. Running it more often doesn't clear "more" senescent cells (they haven't re-accumulated yet) and only stacks toxicity. Long-term primate work at quarterly cadence for two years confirmed clean safety at this schedule:

"Two years of quarterly dasatinib plus quercetin therapy in nonhuman primates led to reductions in markers of inflammation without adverse effects on metabolic, hematologic, or renal parameters." — Ruggiero AD, Vemuri R, Blawas M, et al. GeroScience (2023)

Downstream Effects on Tissue Function#

Translating senescent-cell clearance into outcomes the reader cares about:

• Joint and tendon recovery — senescent chondrocytes and tenocytes drive cartilage loss and tendon stiffness; clearing them is mechanistically aligned with the "my elbows feel better" reports experienced users describe 2–4 weeks post-pulse.
• Adipose tissue insulin sensitivity — senescent preadipocytes impair glucose handling; their clearance improves insulin signalling, relevant for recomp-focused users and anyone running GH or slin.
• Vascular function — senescent endothelial cells drive arterial stiffness; D+Q in animal work improves vasomotor function, which pairs naturally with a low-dose tadalafil longevity stack.
• Skin and connective tissue — the effects here are real but modest and systemic, not a direct dermal treatment. Don't run D+Q for skin.

The signal from this compound does not show up tomorrow. It shows up across months in bloodwork (CRP, IL-6 trending down), in joint feel, and — on the population scale the Mayo group is building — in healthspan trajectories. It's a patience compound, run with discipline on a defined cadence, not a stimulant you "feel."

Common (most users)#

Pulsed D+Q dosing (2–3 days, then nothing for months) is remarkably well-tolerated compared to the chronic daily CML protocol. Most of what users report is mild and self-limiting:

• Transient fatigue on dosing days — expected. Dose in the evening if it bothers you; don't schedule heavy training on pulse days.
• Mild GI upset / nausea — take with a light low-fat meal (not a big meal — absorption is pH-sensitive) or split the dose if it hits hard.
• Heartburn / reflux — dasatinib is pH-dependent, so PPIs and H2 blockers are out on dosing days. If you need acid control, use a calcium carbonate antacid spaced 2+ hours from the dose.
• Mild headache — hydrate aggressively; a single dose of acetaminophen is fine. Skip NSAIDs on dosing days (bleeding synergy).
• Bruising more easily for 24–72h post-dose — SRC-family inhibition transiently impairs platelet function. Don't do BJJ, contact sports, or max-effort lifts during the pulse.

"Short-term, intermittent dosing of dasatinib and quercetin was feasible and well tolerated with no dose-limiting toxicities reported in patients with idiopathic pulmonary fibrosis." — Justice JN et al., EBioMedicine (2019)

Uncommon (dose-dependent or individual)#

Show up more often in users who dose too frequently, stack CYP3A4 inhibitors, or have pre-existing issues:

• Minor transaminase (ALT/AST) bumps — usually normalize by the next cycle. Check a CMP 2 weeks after the first pulse. If ALT is >2× ULN, space cycles further apart and cut alcohol.
• Transient thrombocytopenia / neutropenia dips — mild, transient with pulsed dosing. CBC at baseline and 2 weeks post-first-cycle. Hold further cycles if platelets drop below 100k.
• Fluid retention / mild peripheral edema — more common at 140 mg than 100 mg. Back down to 100 mg or shorten the pulse to 2 days.
• Diarrhea — dose-dependent. Usually responds to reducing to 50 mg × 2 days for the next cycle.
• Rash — drop the dose or extend the interval between cycles; oral antihistamine is fine for mild cases.
• Palpitations / chest awareness — dasatinib prolongs QT modestly. If you feel it, get an ECG before the next cycle and audit for other QT-prolonging drugs (ondansetron, macrolides, some SSRIs).

"Two years of quarterly dasatinib plus quercetin therapy in nonhuman primates led to reductions in markers of inflammation without adverse effects on metabolic, hematologic, or renal parameters." — Ruggiero AD et al., GeroScience (2023)

Rare but serious#

These are the headline toxicities from chronic daily CML dosing. They are rare on a pulsed senolytic schedule but you need to know the warning signs:

• Pleural effusion — the signature dasatinib toxicity in CML. Presents as unexplained dyspnea, dry cough, or chest tightness developing over days to weeks. Rare on pulsed dosing but documented. Stop and get imaging.
• Pulmonary arterial hypertension — progressive shortness of breath on exertion, leg swelling, fatigue. Rare, usually reversible on discontinuation.
• Serious bleeding (GI, intracranial) — SRC-mediated platelet dysfunction plus any underlying lesion. Black stools, unusual bruising, severe headache → stop immediately.
• QT prolongation → arrhythmia — rare at pulsed doses in healthy users; risk compounds with other QT-prolonging drugs or electrolyte disturbances (low K⁺, low Mg²⁺).
• Severe myelosuppression — unlikely on quarterly pulses but possible with over-frequent cycling. Unexplained infections, prolonged bleeding, profound fatigue → CBC.

The pulse protocol was specifically designed around the short half-life (3–5 h) to avoid these chronic toxicities. Running it monthly instead of quarterly long-term starts to edge you toward the exposure profile that causes trouble.

Hard contraindications#

• Pregnancy or active conception attempts — dasatinib is pregnancy category D (teratogenic). Stop at least one full cycle (3+ months) before any conception attempt, for either partner.
• Active anticoagulation (warfarin, DOACs, therapeutic heparin) or recent GI bleed — additive bleeding risk via platelet-function inhibition. Do not run D+Q.
• Existing pleural effusion or pulmonary arterial hypertension — dasatinib can worsen both.
• Congenital long QT syndrome or concurrent class III antiarrhythmics (amiodarone, sotalol) — do not stack.
• Strong CYP3A4 inhibitors on dosing days — ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit. Can 5× AUC and push you into toxicity territory. Space by at least 72 hours before and after the pulse.
• Strong CYP3A4 inducers — rifampin, carbamazepine, St. John's Wort will tank levels; the pulse won't do anything. Not dangerous, just useless.
• Active severe infection or severe thrombocytopenia (<75k) — defer the cycle.
• PPIs, H2 blockers, or antacids co-dosed with dasatinib — not a safety contraindication, but absorption collapses. If you need acid suppression, plan the pulse around it.

Sex-specific and stack considerations#

Women: same pulsed protocol, same doses — no sex differences in PK or senolytic response. The pregnancy contraindication is absolute; use reliable contraception during and for one cycle after dosing. Nursing mothers should not use it.

Men trying to conceive: limited human fertility data, but animal studies show testicular effects at chronic doses. Stop 3+ months before planned conception to allow a full spermatogenesis cycle.

Stacking flags:

• Rapamycin — stagger by 48+ hours. Don't dose on the same day.
• Metformin, low-dose tadalafil, GH peptides, TRT — no interaction, run as normal.
• AAS cycles — run D+Q during a cruise or off-cycle, not mid-blast. The transient platelet dysfunction plus heavy training is an avoidable bruising/injury risk, and you don't want LFT noise confounding cycle bloodwork.
• SSRIs, ondansetron, macrolide antibiotics — QT-prolongation stack; avoid on dosing days.
• Alcohol — skip it on dosing days. Additive hepatic load for no benefit.

PCT: none required. Dasatinib is not hormonally active and has no effect on the HPTA.